ARTICLE | Emerging Company Profile

IPD spinout Vilya computing new paths to oral macrocycle therapies

Vilya is putting the Baker lab’s protein design tools to work finding oral compounds that can target intracellular protein-protein interactions

September 7, 2022 12:03 AM UTC

Arch-backed newco Vilya Inc. is taking the Institute for Protein Design’s toolkit into the macrocycle space, with the goal of designing oral therapies that can pass through cell membranes like small molecules, but have the protein-targeting capabilities of biologics.

The Seattle-based company debuted last week with a tranched $50 million series A round from Arch Venture Partners, and a paper in Cell describing the first disclosed technology in its arsenal: computationally designed macrocyclic peptides that can cross plasma membranes...